Benzinga · Aug 11, 2026
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13
Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $14 to $13.
VS
NASDAQ · VSTM
Verastem, Inc.
Healthcare · Biotechnology
$6.58
Down-$0.09 (-1.35%)
Updated Aug 15, 2026, 3:58 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 571.48M
- P/E ratio
- -3.75
- Dividend yield
- 0.00%
- 52-week range
- $3.43 – $7.18
- Volume
- 1.28M
- Avg. volume
- 2.24M
Price performance
VSTM price history
1M range · 21 trading sessions · Daily adjusted prices
VSTM closed at $6.58 after 21 trading sessions, up 9.12% for the selected period.
- Last close
- $6.58
- Period change
- +9.12%
- Period low
- $5.69
- Period high
- $7.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $6.66 | $6.66 | $6.44 | $6.58 | 1.28M |
| Aug 13, 2026 | $7.06 | $7.06 | $6.64 | $6.67 | 1.86M |
| Aug 12, 2026 | $7.01 | $7.1014 | $6.8905 | $6.95 | 1.26M |
| Aug 11, 2026 | $6.71 | $7.179 | $6.624 | $7.05 | 2.09M |
| Aug 10, 2026 | $6.67 | $6.835 | $6.34 | $6.79 | 2.3M |
| Aug 7, 2026 | $6.65 | $7.10 | $6.02 | $6.74 | 4.32M |
| Aug 6, 2026 | $5.91 | $6.00 | $5.73 | $5.91 | 2.19M |
| Aug 5, 2026 | $5.88 | $5.9709 | $5.775 | $5.87 | 1.55M |
| Aug 4, 2026 | $5.64 | $5.89 | $5.64 | $5.81 | 1.79M |
| Aug 3, 2026 | $5.81 | $5.845 | $5.58 | $5.69 | 1.29M |
| Jul 31, 2026 | $6.04 | $6.09 | $5.54 | $5.80 | 1.86M |
| Jul 30, 2026 | $5.92 | $6.165 | $5.705 | $6.10 | 1.45M |
| Jul 29, 2026 | $6.24 | $6.31 | $5.82 | $6.01 | 2.25M |
| Jul 28, 2026 | $6.06 | $6.25 | $5.9446 | $6.23 | 1.28M |
| Jul 27, 2026 | $6.17 | $6.4643 | $6.065 | $6.08 | 2.24M |
| Jul 24, 2026 | $6.20 | $6.25 | $5.845 | $6.05 | 2.53M |
| Jul 23, 2026 | $5.87 | $6.305 | $5.75 | $6.18 | 2.19M |
| Jul 22, 2026 | $6.01 | $6.1099 | $5.745 | $5.89 | 1.34M |
| Jul 21, 2026 | $5.70 | $6.10 | $5.70 | $6.00 | 2.53M |
| Jul 20, 2026 | $6.04 | $6.215 | $5.71 | $5.75 | 2.53M |
| Jul 17, 2026 | $5.70 | $6.07 | $5.555 | $6.03 | 3.56M |
Latest VSTM news
The latest Smart Investors Daily articles mentioning VSTM.
Stock researchCompany · Overview
VSTM research
Overview
Company profile and research snapshot.
Company profile
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Mizuho | Outperform | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| Jul 2, 2026 | BTIG | Buy | — |
| Jun 24, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.
SeekingAlpha · Aug 7, 2026
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Verastem, Inc. (VSTM) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsJulissa Viana - Vice President of Corporate Communications &...
SeekingAlpha · Aug 7, 2026
Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Verastem, Inc.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
